{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:26:59Z","timestamp":1715992019439},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2007,8,29]],"date-time":"2007-08-29T00:00:00Z","timestamp":1188345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2007,10,2]]},"DOI":"10.1007\/s10585-007-9093-7","type":"journal-article","created":{"date-parts":[[2007,8,28]],"date-time":"2007-08-28T08:05:33Z","timestamp":1188288333000},"page":"567-574","source":"Crossref","is-referenced-by-count":14,"title":["Serum angiogenin levels predict treatment response in patients with stage IV melanoma"],"prefix":"10.1007","volume":"24","author":[{"given":"Pia","family":"Vihinen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minna","family":"Kallioinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meri-Sisko","family":"Vuoristo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Ivaska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari J.","family":"Syrj\u00e4nen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjo","family":"Hahka-Kemppinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pirkko-Liisa","family":"Kellokumpu-Lehtinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seppo O.","family":"Pyrh\u00f6nen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,8,29]]},"reference":[{"issue":"1","key":"9093_CR1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0378-1119(87)90158-2","volume":"56","author":"P Denefle","year":"1987","unstructured":"Denefle P, Kovarik S, Guitton JD et\u00a0al (1987) Chemical synthesis of a gene coding for human angiogenin, its expression in Escherichia coli and conversion of the product into its active form. Gene 56(1):61\u201370","journal-title":"Gene"},{"issue":"23","key":"9093_CR2","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1158\/1078-0432.CCR-05-0962","volume":"11","author":"TM Katona","year":"2005","unstructured":"Katona TM, Neubauer BL, Iversen PW et\u00a0al (2005) Elevated expression of angiogenin in prostate cancer and its precursors. Clin Cancer Res 11(23):8358\u20138363","journal-title":"Clin Cancer Res"},{"issue":"5","key":"9093_CR3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/path.1740","volume":"205","author":"L Campo","year":"2005","unstructured":"Campo L, Turley H, Han C et\u00a0al (2005) Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival. J Pathol 205(5):585\u2013591","journal-title":"J Pathol"},{"issue":"9","key":"9093_CR4","first-page":"3545","volume":"6","author":"T Etoh","year":"2000","unstructured":"Etoh T, Shibuta K, Barnard GF et\u00a0al (2000) Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res 6(9):3545\u20133551","journal-title":"Clin Cancer Res"},{"issue":"6","key":"9093_CR5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.leukres.2003.11.002","volume":"28","author":"FJ Giles","year":"2004","unstructured":"Giles FJ, Vose JM, Do KA et\u00a0al (2004) Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin\u2019s lymphoma or Hodgkin\u2019s lymphoma. Leuk Res 28(6):595\u2013604","journal-title":"Leuk Res"},{"issue":"4","key":"9093_CR6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1245\/ASO.2003.10.002","volume":"10","author":"Y Chao","year":"2003","unstructured":"Chao Y, Li CP, Chau GY et\u00a0al (2003) Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 10(4):355\u2013362","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"9093_CR7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.0307-7772.2001.00519.x","volume":"27","author":"JJ Homer","year":"2002","unstructured":"Homer JJ, Greenman J, Stafford ND (2002) Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci 27(1):32\u201337","journal-title":"Clin Otolaryngol Allied Sci"},{"issue":"1","key":"9093_CR8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/cncr.21136","volume":"104","author":"H Zhao","year":"2006","unstructured":"Zhao H, Grossman HB, Delclos GL et\u00a0al (2006) Increased plasma levels of angiogenin and the risk of bladder carcinoma: from initiation to recurrence. Cancer 104(1):30\u201335","journal-title":"Cancer"},{"issue":"2","key":"9093_CR9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/01.cmr.0000215029.62199.4c","volume":"16","author":"J Song","year":"2006","unstructured":"Song J, Wang J, Yang J et\u00a0al (2006) Influence of angiogenin on the growth of A375 human melanoma cells and the expression of basic fibroblast growth factor. Melanoma Res 16(2):119\u2013126","journal-title":"Melanoma Res"},{"issue":"7","key":"9093_CR10","first-page":"1578","volume":"59","author":"A Hartmann","year":"1999","unstructured":"Hartmann A, Kunz M, Kostlin S et\u00a0al (1999) Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 59(7):1578\u20131583","journal-title":"Cancer Res"},{"issue":"2","key":"9093_CR11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1200\/JCO.2001.19.2.577","volume":"19","author":"S Ugurel","year":"2001","unstructured":"Ugurel S, Rappl G, Tilgen W et\u00a0al (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19(2):577\u2013583","journal-title":"J Clin Oncol"},{"issue":"4","key":"9093_CR12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00008390-200508000-00010","volume":"15","author":"MS Vuoristo","year":"2005","unstructured":"Vuoristo MS, Hahka-Kemppinen M, Parvinen LM et\u00a0al (2005) Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. Melanoma Res 15(4):291\u2013296","journal-title":"Melanoma Res"},{"issue":"6","key":"9093_CR13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1600-0609.2004.00253.x","volume":"72","author":"C Musolino","year":"2004","unstructured":"Musolino C, Alonci A, Bellomo G et\u00a0al (2004) Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications. Eur J Hematol 72(6):416\u2013419","journal-title":"Eur J Hematol"},{"issue":"4","key":"9093_CR14","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1200\/JCO.2001.19.4.1207","volume":"19","author":"RT Poon","year":"2001","unstructured":"Poon RT, Fan ST, Wong J (2001) Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19(4):1207\u20131225","journal-title":"J Clin Oncol"},{"issue":"2","key":"9093_CR15","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1046\/j.1365-2141.2001.02921.x","volume":"114","author":"S Verstovsek","year":"2001","unstructured":"Verstovsek S, Kantarjian H, Aguayo A et\u00a0al (2001) Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. Br J Haematol 114(2):290\u2013295","journal-title":"Br J Haematol"},{"issue":"8","key":"9093_CR16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s004320000138","volume":"126","author":"S Shimoyama","year":"2000","unstructured":"Shimoyama S, Kaminishi M (2000) Increased angiogenin expression in gastric cancer correlated with cancer progression. J Cancer Res Clin Oncol 126(8):468\u2013474","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2B","key":"9093_CR17","first-page":"1045","volume":"22","author":"S Shimoyama","year":"2002","unstructured":"Shimoyama S, Shimizu N, Tsuji E et\u00a0al (2002) Distribution of angiogenin and its gene message in colorectal cancer patients and their clinical relevance. Anticancer Res 22(2B):1045\u20131052","journal-title":"Anticancer Res"},{"issue":"7","key":"9093_CR18","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.clinbiochem.2004.05.012","volume":"37","author":"R Harpio","year":"2004","unstructured":"Harpio R, Einarsson R (2004) S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 37(7):512\u2013518","journal-title":"Clin Biochem"},{"issue":"3","key":"9093_CR19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00008390-200010030-00005","volume":"10","author":"MS Vuoristo","year":"2000","unstructured":"Vuoristo MS, Kellokumpu-Lehtinen P, Laine S et\u00a0al (2000) The value of serum S-100b and interleukins as tumour markers in advanced melanoma. Melanoma Res 10(3):237\u2013241","journal-title":"Melanoma Res"},{"issue":"3B","key":"9093_CR20","first-page":"2203","volume":"20","author":"D Dlukanovic","year":"2000","unstructured":"Dlukanovic D, Hofmann U, Sucker A et\u00a0al (2000) Comparison of S100 and MIA protein as serum marker for malignant melanoma. Anticancer Res 20(3B):2203\u20132207","journal-title":"Anticancer Res"},{"issue":"1","key":"9093_CR21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2230.2005.01992.x","volume":"31","author":"P Vereecken","year":"2006","unstructured":"Vereecken P, Zouaoui Boudjeltia K, Depray C et\u00a0al (2006) High serum galectin-3 in advanced melanoma: preliminary results. Clin Exp Dermatol 31(1):105\u2013109","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"9093_CR22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/107327480200900102","volume":"9","author":"CJ Kim","year":"2002","unstructured":"Kim CJ, Reintgen DS, Balch CM (2002) The new melanoma staging system. Cancer Control 9(1):9\u201315","journal-title":"Cancer Control"},{"issue":"5","key":"9093_CR23","first-page":"1282","volume":"7","author":"S Ugurel","year":"2001","unstructured":"Ugurel S, Rappl G, Tilgen W et\u00a0al (2001) Increased soluble CD95 (sFas\/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 7(5):1282\u20131286","journal-title":"Clin Cancer Res"},{"issue":"14","key":"9093_CR24","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1158\/1078-0432.CCR-04-2478","volume":"11","author":"J Nikkola","year":"2005","unstructured":"Nikkola J, Vihinen P, Vuoristo MS et\u00a0al (2005) High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 11(14):5158\u20135166","journal-title":"Clin Cancer Res"},{"issue":"6","key":"9093_CR25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00008390-200512000-00006","volume":"15","author":"S Brennecke","year":"2005","unstructured":"Brennecke S, Deichmann M, Naeher H et\u00a0al (2005) Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res 15(6):515\u2013522","journal-title":"Melanoma Res"},{"issue":"1B","key":"9093_CR26","first-page":"595","volume":"27","author":"MG Cao","year":"2007","unstructured":"Cao MG, Auge JM, Molina R et\u00a0al (2007) Melanoma inhibiting activity protein (MIA) beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma. Anticancer Res 27(1B):595\u2013599","journal-title":"Anticancer Res"},{"issue":"1","key":"9093_CR27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ijc.21820","volume":"119","author":"SR Reynolds","year":"2006","unstructured":"Reynolds SR, Vergilis IJ, Szarek M et\u00a0al (2006) Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy? Int J Cancer 119(1):157\u2013161","journal-title":"Int J Cancer"},{"issue":"4","key":"9093_CR28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00008390-200208000-00006","volume":"12","author":"R Mouawad","year":"2002","unstructured":"Mouawad R, Antoine EC, Gil-Delgado M et\u00a0al (2002) Serum caspase-1 levels in metastatic melanoma patients: relationship with tumor burden and non-response to biochemotherapy. Melanoma Res 12(4):343\u2013348","journal-title":"Melanoma Res"},{"issue":"12","key":"9093_CR29","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1158\/0008-5472.CAN-04-0957","volume":"64","author":"A Fujimoto","year":"2004","unstructured":"Fujimoto A, O\u2019Day SJ, Taback B et\u00a0al (2004) Allelic imbalance on 12q22\u201323 in serum circulating DNA of melanoma patients predicts disease outcome. Cancer Res 64(12):4085\u20134088","journal-title":"Cancer Res"},{"issue":"7","key":"9093_CR30","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","volume":"25","author":"RH Vonderheide","year":"2007","unstructured":"Vonderheide RH, Flaherty KT, Khalil M et\u00a0al (2007) Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25(7):876\u2013883","journal-title":"J Clin Oncol"},{"issue":"19","key":"9093_CR31","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1200\/JCO.2005.05.2498","volume":"24","author":"SJ Moschos","year":"2006","unstructured":"Moschos SJ, Edington HD, Land SR et\u00a0al (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24(19):2164\u20133171","journal-title":"J Clin Oncol"},{"issue":"11","key":"9093_CR32","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2004.11.070","volume":"22","author":"DC Lev","year":"2004","unstructured":"Lev DC, Onn A, Melinkova VO et\u00a0al (2004) Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 22(11):2092\u20132100","journal-title":"J Clin Oncol"},{"issue":"2","key":"9093_CR33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/jcp.20137","volume":"202","author":"M Caraglia","year":"2005","unstructured":"Caraglia M, Marra M, Pelaia G et\u00a0al (2005) Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol 202(2):323\u2013335","journal-title":"J Cell Physiol"},{"issue":"2","key":"9093_CR34","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/1097-0142(20010715)92:2<369::AID-CNCR1332>3.0.CO;2-U","volume":"92","author":"S Ugurel","year":"2001","unstructured":"Ugurel S, Rebmann V, Ferrone S et\u00a0al (2001) Soluble human leukocyte antigen G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 92(2):369\u2013376","journal-title":"Cancer"},{"issue":"3","key":"9093_CR35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2613.2006.00478.x","volume":"87","author":"MR Hussein","year":"2006","unstructured":"Hussein MR (2006) Tumour-associated macrophages and melanoma tumorigenesis: integrating the complexity. Int J Exp Pathol 87(3):163\u2013176","journal-title":"Int J Exp Pathol"},{"issue":"10","key":"9093_CR36","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Chen HL, Girgis KR et\u00a0al (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2(10):1096\u20131103","journal-title":"Nat Med"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-007-9093-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10585-007-9093-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-007-9093-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T14:32:52Z","timestamp":1559226772000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-007-9093-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,29]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,10,2]]}},"alternative-id":["9093"],"URL":"https:\/\/doi.org\/10.1007\/s10585-007-9093-7","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,29]]}}}